Enzo Biochem to Market Sequenom's MaterniT21 Plus Test | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem today said that it has signed an agreement to market Sequenom's MaterniT21 Plus test service in the northeast US.

The sequencing-based test, which is performed at the Sequenom Center for Molecular Medicine, analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. It is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.